Top

Published in:

Open Access 01-12-2013 | Research

BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy

Authors: Michael R Pranzatelli, Elizabeth D Tate, Nathan R McGee, Anna L Travelstead, Jerry A Colliver, Jayne M Ness, Richard M Ransohoff

Published in: Journal of Neuroinflammation | Issue 1/2013

Abstract

Background

B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder.

Objective

To assess the role of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two critical B cell-modulating cytokines, as potential biomarkers of disease activity and treatment biomarkers in OMS.

Methods

Soluble BAFF and APRIL were measured in cerebrospinal fluid (CSF) and serum by ELISA in 433 children (296 OMS, 109 controls, 28 other inflammatory neurological disorders (OIND)). BAFF-R receptors on circulating CD19+ B cells were measured by flow cytometry. A blinded scorer rated motor severity on the OMS Evaluation Scale. Immunotherapies were evaluated cross-sectionally and longitudinally.

Results

The mean CSF BAFF concentration, which was elevated in untreated OMS and OIND, correlated with OMS severity category (P = 0.006), and reduction by adrenocorticotropic hormone or corticotropin (ACTH) (−61%) or corticosteroids (−38%) was seen at each level of severity. In contrast, CSF APRIL was normal in OMS and OIND and unaffected by immunotherapy. When the entire OMS dataset was dichotomized into ‘high’ versus ‘normal’ CSF BAFF concentration, the phenotype of the high group included greater motor severity and number of CSF oligoclonal bands, and a higher concentration of inflammatory chemokines CXCL13 and CXCL10 in CSF and CXCL9 and CCL21 in serum. Serum APRIL was 6.7-fold higher in the intravenous immunoglobulins (IVIg) group, whereas serum BAFF was 2.6-fold higher in the rituximab group. The frequency of B cell BAFF-R expression was similar in untreated and treated OMS. Longitudinal studies of CSF BAFF revealed a significant decline in ACTH-treated patients (with or without rituximab) (P < 0.0001). Longitudinal studies of serum APRIL showed a 2.9-fold increase after 1 to 2 g/kg IVIg monotherapy (P = 0.0003).

Conclusions

Striking distinctions in BAFF/APRIL signaling were found. OMS displayed heterogeneity in CSF BAFF expression, which met many but not all criteria as a potential biomarker of disease activity. We speculate that CSF BAFF may have more utility in a biomarker panel than as a stand-alone biomarker, and that the selective upregulation of both serum APRIL by IVIg and BAFF by rituximab, as well as downregulation of CSF BAFF by ACTH/steroids, may have utility as treatment biomarkers.

Tate ED, Pranzatelli MR, Verhulst SJ, Markwell SJ, Franz DN, Graf WD, Joseph SA, Khakoo YN, Lo WD, Mitchell WG, Sivaswamy L: Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 2012, 27:875–884.CrossRefPubMed

Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ: CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004, 19:770–777.CrossRefPubMed

Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Ransohoff RM, Ness JM, Colliver JA: Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol 2012, 243:81–88.CrossRefPubMed

Pranzatelli MR, Tate ED, Hoefgen ER, Verhulst SJ: Interferon-inducible protein 10 (CXCL10) is increased in the cerebrospinal fluid of children with opsoclonus-myoclonus syndrome. Ann Neurol 2007, Suppl 11:S112-S113.

Pranzatelli MR, Slev PR, Tate ED, Travelstead AD, Colliver JA, Joseph SA: Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol 2011, 45:27–33.CrossRefPubMed

Daridon C, Youinou P, Pers JO: BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun Rev 2008, 7:267–271.CrossRefPubMed

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747–1756.CrossRefPubMedPubMedCentral

Rickert RC, Jellusova J, Miletic AV: Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011, 244:115–133.CrossRefPubMedPubMedCentral

Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E: BAFF is produced by astrocytes and up-regulated in multiple sclerosis legions and primary central nervous system lymphoma. J Exp Med 2005, 201:195–200.CrossRefPubMedPubMedCentral

10.

Thangarajh M, Kisiswa L, Pirskanen R, Hillert J: The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand J Immunol 2007, 65:461–466.CrossRefPubMed

11.

Mackay F, Silveira PA, Brink R: B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007, 19:327–336.CrossRefPubMed

12.

George-Chandy A, Trysberg E, Eriksson K: Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008, 10:R97.CrossRefPubMedPubMedCentral

13.

Hamzaoui K, Houman H, Hentati F, Hamzaoui A: BAFF is up-regulated in central nervous system of neuro-Behcet’s disease. J Neuroimmunol 2008, 200:111–114.CrossRefPubMed

14.

Hopia L, Thangarajh M, Khademi M, Laveskog A, Wallström E, Svenungsson E, Andersson M: Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2011, 40:363–372.CrossRefPubMed

15.

Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807–817.CrossRefPubMed

16.

Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA: Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008, 44:26–32.CrossRefPubMed

17.

Kivisäkk P, Liu Z, Trebst C, Tucky B, Wu L, Stine J, Mack M, Rudick RA, Campbell JJ, Ransohoff RM: Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 2003, 29:319–325.CrossRefPubMed

18.

Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y: Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:3692–3701.CrossRefPubMed

19.

Piazza F, DiFrancesco JC, Fusco ML, Corti D, Pirovano L, Frigeni B, Mattavelli L, Andreoni S, Frigo M, Ferrarese C, Tredici G, Cavaletti G: Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol 2010, 220:104–107.CrossRefPubMed

20.

Ragheb S, Li Y, Simon K, Van Haerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R: Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011, 17:819–829.CrossRefPubMed

21.

Franciotta D, Di Stefano AL, Jarius S, Zardini E, Tavazzi E, Ballerini C, Marchioni E, Bergamaschi R, Ceroni M: Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol 2011, 230:160–163.CrossRefPubMed

22.

Treml JF, Hao Y, Stadanlick JE, Cancro MP: The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009, 53:1–16.CrossRefPubMed

23.

Xiao Y, Motomura S, Podack ER: APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol 2008, 38:3450–3458.CrossRefPubMedPubMedCentral

24.

Doi M, Takeda T, Sakurai Y, Kato J, Hayashi T, Fukuda K, Takase T, Shima M: Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol 2010, 20:413–418.PubMed

25.

Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ: Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. Cytokine 2011, 53:384–389.CrossRefPubMed

26.

Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E: BAFF is elevated in serum of patients with Wegener’s granulomatosis. J Autoimmun 2005, 25:298–302.CrossRefPubMed

27.

Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM: Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1096–1103.CrossRefPubMedPubMedCentral

28.

Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO: Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007, 1110:426–432.CrossRefPubMed

29.

Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.CrossRefPubMedPubMedCentral

30.

Fühlhuber V, Bick S, Kirsten A, Hahn A, Gerriets T, Tschernatsch M, Kaps M, Preissner KT, Blaes F, Altenkämper S: Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009, 210:87–91.CrossRefPubMed

31.

Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A, Lougaris V, Quinti I, Thon V, Litzman J, Schlesier M, Warnatz K, Thiel J, Rolink AG, Eibel H: Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012, 188:497–503.CrossRefPubMed

Title: BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
Authors: Michael R Pranzatelli
Elizabeth D Tate
Nathan R McGee
Anna L Travelstead
Jerry A Colliver
Jayne M Ness
Richard M Ransohoff
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2013
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/1742-2094-10-10

Keynote webinar | Spotlight on medication adherence

Springer Medicine

BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Different actions of endothelin-1 on chemokine production in rat cultured astrocytes: reduction of CX3CL1/fractalkine and an increase in CCL2/MCP-1 and CXCL1/CINC-1

Toll-like receptor 4 signaling in trigeminal ganglion neurons contributes tongue-referred pain associated with tooth pulp inflammation

Amyloid-β peptide-induced extracellular S100A9 depletion is associated with decrease of antimicrobial peptide activity in human THP-1 monocytes

Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain

Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes

The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity